Abstract PS5-02-20: Treatment patterns and outcomes of sacituzumab govitecan in older versus younger patients with mTNBC: multinational real-world data
Aleksandra Konieczna, Miloš Holánek, M. Pieniazek, Justyna Żubrowska et autres
Abstract Background: Patients over 65 years constitute a substantial subset of those diagnosed with metastatic triple-negative breast cancer (mTNBC), yet are frequently underrepresented in clinical trials due to comorbidities, frailty, and polypharmacy. Sacituzumab govitecan (SG), approved for pretreated mTNBC, demonstrated comparable efficacy …
hu, cz, pl, sk, gb (code pays fourni par la source)
0 citations
Clinical Cancer Research